<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>

J Mark Fitzgerald; Eugene R. Bleecker; Arnaud Bourdin; William Busse; Gary Ferguson; Laura Brooks; Peter Barker; Ubaldo Martin

doi:10.2147/JAA.S227170

Back

<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>

Journal article

Open access

Peer reviewed

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

J Mark Fitzgerald, Eugene R. Bleecker, Arnaud Bourdin, William Busse, Gary Ferguson, Laura Brooks, Peter Barker and Ubaldo Martin

Journal of Asthma and Allergy, Vol.Volume 12, pp.401-413

2019

DOI: https://doi.org/10.2147/JAA.S227170

PMID: 31849500

Abstract

asthma

benralizumab

clinical features

eosinophilic inflammation

interleukin-5 receptor

safety

Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.2147/JAA.S227170View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
Creators - without role: J Mark Fitzgerald - Vancouver General Hospital
Eugene R. Bleecker - University of Arizona
Arnaud Bourdin - Université de Montpellier, Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
William Busse - University of Wisconsin–Madison
Gary Ferguson - Southeast
Laura Brooks - AstraZeneca
Peter Barker - AstraZeneca
Ubaldo Martin - AstraZeneca
Publication Details: Journal of Asthma and Allergy, Vol.Volume 12, pp.401-413
Identifiers: 9942665509311
Academic Unit: Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Language: English
Resource Type: Journal article
Local Fields: hal-02419280